Key result
MiR-92b expression in peripheral plasma was down-regulated in patients with hypertension and heart disease, showing a positive correlation with LVEF and negative correlation with LVMI.
Why the study?
The study was conducted to investigate the correlation between peripheral plasma miR-92b expression and hypertension, heart disease, and cerebral hemorrhage.
Does miR-92b expression correlate with the severity of hypertension, hypertensive left ventricular hypertrophy, heart failure, and cerebral hemorrhage?
Observational (n=264)
No
Does miR-92b expression correlate with the severity of hypertension, hypertensive left ventricular hypertrophy, heart failure, and cerebral hemorrhage?
Down-regulation of miR-92b in peripheral plasma correlates with the severity of hypertension, left ventricular hypertrophy, heart failure, and cerebral hemorrhage, highlighting its potential as a biomarker.
Answers are grounded in this paper and cite their sources.
Plasma miR-92b may associate with hypertensive disease progression; leaves open biomarker utility pending prospective validation.
Objective: To delve into the correlation between miR-92b expression in peripheral plasma and hypertension, heart disease and cerebral hemorrhage. Methods: We enrolled 204 patients hospitalized in our institution from March 2016 to May 2017, including patients with hypertension (group B), hypertensive left ventricular hypertrophy (HTN-LVH) (group C), HTN-LVH complicated heart failure (group D), with 68 cases each group, and recruited another 60 healthy volunteers as control group (group A). Our team compared miR-92b level in peripheral plasma, and ultrasound indexes among the four groups and inquired into their correlation. The patients were followed up to assay miR-92b level in the peripheral plasma, cerebral edema volume and cerebral hematoma volume before and after treatment. Results: (1) In contrast to group B, the LVDs and LVMI in group C, D waxed, whereas LVEF and E/A waned (P<0.05). In contrast to group C, group D owned increased LVDs and LVMI, and decreased LVEF (all P<0.05). (2) In contrast to group A, miR-92b expression decreased in groups B, C and D, among which group D were the lowest and group B were the highest (all P<0.05). (3) miR-92b held negative relationship with SBP, DBP, LVDd and LVMI (all P<0.001), and had positive link with LVEF (r=0.649, P<0.001). (4) In contrast to before treatment, miR-92b expression in plasma was up-regulated after treatment (P<0.05). miR-92b level in plasma after treatment possessed negative association with brain edema volume and hematoma volume (P<0.001), and no correlation with the edema/hematoma ratio. Conclusion: miR-92b expression in peripheral plasma of patients with hypertension, myocardial hypertrophy and cerebral hemorrhage is down-regulated. miR-92b probably harbors a defensive impact and participates in the pathophysiological process of hypertension, heart disease and cerebral hemorrhage.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2020) conducted an observational in Hypertension, hypertensive left ventricular hypertrophy, and heart failure (n=264). miR-92b expression vs. Healthy controls was evaluated on Correlation of miR-92b with left ventricular ejection fraction (LVEF) (r=0.649, 95% CI 0.556-0.727, p=<0.001). MiR-92b expression in peripheral plasma was down-regulated in patients with hypertension and heart disease, showing a positive correlation with LVEF and negative correlation with LVMI.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: